CUMBERLAND PHARMACEUTICALS INC - 8-K Filing
Cumberland Pharmaceuticals delays presentation of long-term safety and efficacy data from its Phase 2 FIGHT DMD trial for ifetroban. (Items: 7.01 Regulation FD Disclosure)
Tickers: $CPIX
More Regulatory news
- Neonode Inc. - 8-K Filing
- Beyond Air, Inc. - 10-Q Filing
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing
- CENTRUS ENERGY CORP - 8-K Filing
- SAGA COMMUNICATIONS INC - 8-K Filing
- NextBoat Inc. - 8-K Filing
- CIVISTA BANCSHARES, INC. - 8-K Filing